JPWO2020160468A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020160468A5
JPWO2020160468A5 JP2021544752A JP2021544752A JPWO2020160468A5 JP WO2020160468 A5 JPWO2020160468 A5 JP WO2020160468A5 JP 2021544752 A JP2021544752 A JP 2021544752A JP 2021544752 A JP2021544752 A JP 2021544752A JP WO2020160468 A5 JPWO2020160468 A5 JP WO2020160468A5
Authority
JP
Japan
Prior art keywords
cells
optionally
hla
pharmaceutical composition
ncd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523514A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016206 external-priority patent/WO2020160468A1/en
Publication of JP2022523514A publication Critical patent/JP2022523514A/ja
Publication of JPWO2020160468A5 publication Critical patent/JPWO2020160468A5/ja
Priority to JP2024231447A priority Critical patent/JP2025062601A/ja
Pending legal-status Critical Current

Links

JP2021544752A 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法 Pending JP2022523514A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024231447A JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800177P 2019-02-01 2019-02-01
US62/800,177 2019-02-01
PCT/US2020/016206 WO2020160468A1 (en) 2019-02-01 2020-01-31 Compositions and methods for treating neurocognitive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024231447A Division JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2022523514A JP2022523514A (ja) 2022-04-25
JPWO2020160468A5 true JPWO2020160468A5 (enrdf_load_stackoverflow) 2023-04-27

Family

ID=71840202

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544752A Pending JP2022523514A (ja) 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法
JP2024231447A Pending JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024231447A Pending JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Country Status (7)

Country Link
US (1) US20220133808A1 (enrdf_load_stackoverflow)
EP (1) EP3917620A4 (enrdf_load_stackoverflow)
JP (2) JP2022523514A (enrdf_load_stackoverflow)
CA (1) CA3127808A1 (enrdf_load_stackoverflow)
IL (1) IL285270A (enrdf_load_stackoverflow)
MA (1) MA54880A (enrdf_load_stackoverflow)
WO (1) WO2020160468A1 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20210122817A1 (en) 2018-01-31 2021-04-29 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ms4a4a抗体及びその使用方法
US20220378942A1 (en) * 2019-10-01 2022-12-01 Children's Medical Center Corporation Compositions and methods for treating alzheimer's disease
WO2022006105A2 (en) * 2020-07-02 2022-01-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
US20220127347A1 (en) * 2020-10-26 2022-04-28 The Regents Of The University Of California Inhibition of Tau Propagation
CA3214688A1 (en) 2021-04-08 2022-10-13 Andrzej KROLEWSKI Methods of diagnosing and predicting renal decline
WO2023156807A2 (en) * 2021-09-27 2023-08-24 Curelab Oncology, Inc. Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins
WO2024178386A1 (en) * 2023-02-24 2024-08-29 Aarhus Universitet Methods of treating endosomal trafficking diseases
WO2025064926A1 (en) * 2023-09-22 2025-03-27 The Board Of Regents Of The University Of Texas System Novel secretory signal peptides and uses thereof
CN117736321A (zh) * 2023-12-20 2024-03-22 中国人民解放军空军军医大学 一种乙酰化修饰的特异性抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1095154A2 (en) * 1998-07-10 2001-05-02 Curagen Corporation Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
US20050163760A1 (en) * 2001-12-06 2005-07-28 Nathalie Cartier-Lacave Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
US20130102538A1 (en) * 2010-05-05 2013-04-25 Amicus Therapeutics, Inc. Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
WO2015067668A1 (en) * 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) New alzheimer's disease animal model
US11066456B2 (en) * 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
KR102040364B1 (ko) * 2017-05-26 2019-11-05 가천대학교 산학협력단 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법
KR20200032722A (ko) * 2017-07-27 2020-03-26 노파르티스 아게 부분절단효소 내성 trem2 변이체

Similar Documents

Publication Publication Date Title
US11965174B2 (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
US20230295659A1 (en) TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
Dashkoff et al. Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
JP2025015673A (ja) 脊髄軟膜下遺伝子送達システム
Iida et al. Systemic delivery of tyrosine‐mutant AAV vectors results in robust transduction of neurons in adult mice
US8278428B2 (en) Mitochondrial nucleic acid delivery systems
JPWO2020160468A5 (enrdf_load_stackoverflow)
Hoshino et al. The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury
JPWO2020160458A5 (enrdf_load_stackoverflow)
JP2024123093A (ja) 筋萎縮性側索硬化症の治療におけるコレステロール24―ヒドロラーゼの発現ベクター
Minskaia et al. Viral vectors in gene replacement therapy
US20230190893A1 (en) Compositions and methods for treating an inherited retinal disease
US20240408243A1 (en) Methods for upregulating shank3 expression
JPWO2019173756A5 (enrdf_load_stackoverflow)
JP2021526839A (ja) 眼圧及び頭蓋内圧を調節するための材料及び方法
JPWO2020160441A5 (enrdf_load_stackoverflow)
US20240156873A1 (en) Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
WO2024226729A2 (en) Compositions and methods for opa1 gene therapy
JP2024542015A (ja) 脳内でのtcf7l2媒介性髄鞘再生
HK40049414A (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
Seymour et al. European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress 2011 October 27–31, 2011 The Brighton Centre, Brighton United Kingdom
Kojima et al. The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury
HK1240977B (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof